FILTER
FILTERED INTERVIEW RESULTS
Stefan Lepecki
CEO, BRASKEM IDESA
"We work very closely with Pemex and are very confident in their ability."
Cristhian Perez & Ralf van der Ven
VOPAK
“Typically, we see elections as times of uncertainty. However, in the coming year we do not expect a huge impact on the business environment since our business relies on short or long-term positions for basic products.”
Ricardo Diogo
DIRECTOR BUSINESS DEVELOPMENT, OILTANKING MEXICO
Oiltanking plans to operate two terminals in Tuxpan on the Gulf Coast that will import fuels within 18 months.
Eugenio Gerardo Manzano Alba
EXECUTIVE DIRECTOR, POCHTECA
Pochteca plans to grow organically above the rate of GDP growth and through acquisitions.
José Luis Uriegas
CEO, GRUPO IDESA
Grupo Idesa has adjusted to Mexico’s energy reforms and is exploring opportunities upstream.
Edison Terra Filho
EXECUTIVE VICE PRESIDENT, BRASKEM
Braskem's five year investment plan includes a new 450,000 kt/y US PP asset and a firm commitment to develop renewables.
Érica Takeda
MANAGING DIRECTOR, BRENNTAG
Brenntag in Brazil is determined to continue its expansion through acquisitions.
Reinaldo Kröger & Edson de Paiva
PRESIDENT & OPERATIONS DIRECTOR, UNIGEL
Unigel is Latin America’s leading producer of acrylics and styrenics.
Suri Chetty
DIRECTOR, BUSINESS DEVELOPMENT, UNICHEM
Unichem are in partnership with Novvi to bring synthetic renewable and biodegradable hydrocarbon production to South Africa.
Matthew Spalding
DIRECTOR, HYDROCARBONS & CHEMICALS (SE ASIA), WORLEYPARSONS
WorleyParsons is a major ECPM player on Jurong island and is adapting its offering to cope with a faltering demand for new projects.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
